Cook’s Zilver PTX Safety Trial Finds No Stent Fractures
This article was originally published in The Gray Sheet
Executive Summary
Preliminary results of Cook Medical's safety trial for its Zilver PTX paclitaxel-eluting superficial femoral artery stent showed no stent fractures and a major adverse event rate equal to balloon angioplasty, the firm reports